Successful Treatment of Rare Pulmonary Coprinopsis cinerea Infection in a 17-Year-Old Female After Hematopoietic Stem Cell Transplantation: A Case Report
Uet Yu,Ke Cao,Chunlan Yang,Chunjing Wang,Yue Li,Xiaohui Zhou,Qian Zhang,Yuanxiang Wang,Feiqiu Wen,Sixi Liu,Xiaodong Wang
DOI: https://doi.org/10.2147/IDR.S397233
2023-03-18
Infection and Drug Resistance
Abstract:Uet Yu, 1 Ke Cao, 2 Chunlan Yang, 1 Chunjing Wang, 1 Yue Li, 1 Xiaohui Zhou, 1 Qian Zhang, 1 Yuanxiang Wang, 3 Feiqiu Wen, 1 Sixi Liu, 1 Xiaodong Wang 1 1 Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, People's Republic of China; 2 Department of Laboratory Medicine, Shenzhen Children's Hospital, Shenzhen, People's Republic of China; 3 Department of Cardiothoracic Surgery, Shenzhen Children's Hospital, Shenzhen, People's Republic of China Correspondence: Xiaodong Wang; Sixi Liu, Email ; Invasive fungal infections (IFIs) are among the most severe complications in recipients of hematopoietic stem cell transplantation (HSCT) recipients and in patients with hematological malignancies. An increasing number of uncommon fungal infections have been reported in this era of antifungal prophylaxis. Coprinopsis cinerea is a rare pathogen that causes opportunistic infections in the immunocompromised patients, including HSCT recipients and is associated with very high mortality rates. Herein, we present a successfully treated pediatric HSCT patient with breakthrough pulmonary IFI caused by Coprinopsis cinerea despite posaconazole, prophylaxis using multidisciplinary approaches. Keywords: Coprinopsis cinerea , Hormographiella aspergillata , invasive fungal infection, hematopoietic stem cell transplantation, leukemia, case report Invasive fungal infections (IFIs) are among the most severe complications and contribute to high morbidity and mortality in hematopoietic stem cell transplantation (HSCT) recipients and patients with hematological malignancies. 1 Administration of high-dose chemotherapy, immunosuppressive agents, steroids, and broad-spectrum antibiotics increases the incidence of IFIs in HSCT recipients and patients with hematological disorders. 2,3 In addition, IFIs often exhibit rapid disease progression and a slow response to treatment, leading to limitations in diagnosing them and treatment delays. 3 Although antifungal prophylaxis is recommended in most cases of HSCT, the risk of developing an IFI remains high, particularly in patients with co-existing with other complications, such as prolonged neutropenia, severe viral and bacterial infections, and graft-versus-host diseases (GVHDs). 1,2 In addition, IFIs on antifungal prophylaxis in HSCT patients often have an insidious onset, which may increase the risk of misdiagnosis and delay treatment. Candida albicans and Aspergillus spp . are among the most common causative organisms of fungal infections in HSCT recipients and patients with hematological malignancies in China. 4,5 However, there is an increasing number of uncommon fungal infections, which may be associated with a shift in the etiology spectrum of IFIs due to antifungal prophylaxis. 6–8 In this paper, we report a rare case of pulmonary Coprinopsis cinerea ( C. cinerea ) infection in a 17-year-old patient with B-cell acute lymphoblastic leukemia (B-ALL) after HSCT. A 17-year-old female with the second relapse of B-ALL received chimeric antigen T-cell (CART) salvage therapy, followed by co-transplantation of haploidentical stem cells and unrelated cord blood in September 2021. The patient had a previous disseminated pulmonary tuberculosis infection during the first relapse in July 2020. However, she recovered well after treatment with anti-tuberculosis drugs, including isoniazid (10 mg/kg/day), rifampicin (10 mg/kg/day), and levofloxacin (10 mg/kg/day) from July 2020 to April 2021, and continued to receive oral isoniazid prophylaxis until 3 days prior to HSCT. Chest computed tomography (CT) revealed no residual tuberculosis lesions and interferon-gamma (IFN-γ) release assays was negative prior to transplantation. Furthermore, there was no evidence of fungal infection during chemotherapy or prior to HSCT. The patient received a myeloablative conditioning regimen consisting of cyclophosphamide, busulfan, fludarabine, and thiotepa without total body irradiation. The post-transplant immunosuppressants included of post-transplant cyclophosphamide, cyclosporine, and mycophenolate mofetil. In addition, oral posaconazole (200 mg every 8h) was commenced 3 days after HSCT as an antifungal prophylaxis. Additionally, neutrophils and platelets were engrafted on 15 and 24 days after transplantation, respectively. Engraftment syndrome with fever, skin rashes, and elevated bilirubin levels was observed during cell engraftment from day 14 after transplantation. However, these symptoms resolved after intravenous administration of methylprednisolone (1 mg/kg/day for 4 days from day 15 to day 18, after which the dose was -Abstract Truncated-
pharmacology & pharmacy,infectious diseases